CompletedNot Applicable

CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?

1,023 participantsStarted 2012-05-16

Plain-language summary

Patients aged 18-89 with stable CAD and comorbidities receiving optimal medical treatment requiring PCI with iodinated contrast media. The aim of the study is to assess the prevalence of contrast-induced AKI in 2012-2013 and 2017 cohorts and to evaluate the potential risk factors of CI-AKI to better guide the prevention in patients of higher risk.

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Informed consent * Male and female patients 18 y. o. and older * Verified stable coronary artery disease (CAD) * Receiving optimal medical treatment and requiring percutaneous coronary intervention (PCI) with iodinated contrast media Exclusion Criteria: * Pregnancy, lactation * Conditions affecting the prognosis (kidney failure, liver failure, oncology) * Acute coronary syndrome (ACS) * Stroke * Contraindications to PCI * Therapy with nephrotoxic drugs during the enrolment which cannot be stopped * Refusal to sign the informed consent

What they're measuring

Overall mortality

Timeframe: 5 years

Cardiovascular mortality

Timeframe: 5 years

Myocardial infarction

Timeframe: 5 years

Stroke

Timeframe: 5 years

GI bleeding

Timeframe: 5 years

CABG

Timeframe: 5 years

PCI

Timeframe: 5 years

Trial details

NCT IDNCT04014153

SponsorI.M. Sechenov First Moscow State Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-10-19

View on ClinicalTrials.gov More Stable Angina trials